{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:49:03Z","timestamp":1792842543633,"version":"4.5.0"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2005,3,7]],"date-time":"2005-03-07T00:00:00Z","timestamp":1110153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Photoderm Photoimm Photomed"],"published-print":{"date-parts":[[2005,4]]},"abstract":"<jats:p><jats:bold>Background\/Purpose: <\/jats:bold> Mono\u2010<jats:sc>l<\/jats:sc>\u2010aspartyl chlorin e6 (NPe6) is a photosensitizer that exhibits chemical purity, absorption at 664\u2003nm wavelength and may be useful in photodynamic therapy (PDT).<\/jats:p><jats:p><jats:bold>Methods: <\/jats:bold> This open label phase I clinical trial at the University of California, Davis Medical Center examined the pharmacokinetic properties of Npe6 and clinical response to PDT with this photosensitizer. A single intravenous dose of Npe6 was administered to 14 cancer patients with superficial malignancies (basal cell carcinoma=22 lesions, squamous cell cancer=13 lesions, papillary carcinoma=14 lesions). Patients received one of five ascending doses (0.5\u2003mg\/kg (<jats:italic>n<\/jats:italic>=4), 1.0\u2003mg\/kg (<jats:italic>n<\/jats:italic>=3), 1.65\u2003mg\/kg (<jats:italic>n<\/jats:italic>=3), 2.5\u2003mg\/kg (<jats:italic>n<\/jats:italic>=3), or 3.5\u2003mg\/kg (<jats:italic>n<\/jats:italic>=1)) 4\u20138\u2003h prior to light activation. The total light dose (range 25\u2013200\u2003J\/cm<jats:sup>2<\/jats:sup>) depended on the tumor shape and size. Light was delivered using an argon\u2010pumped tunable dye laser. Serum NPe6 concentrations were measured over a 28\u2010day period. The toxicity and cutaneous clinical efficacy of NPe6 were observed.<\/jats:p><jats:p><jats:bold>Results: <\/jats:bold> Four weeks post\u2010PDT, 20 of 22 basal cell carcinoma tumors (91%) showed a complete response. Eighteen of 27 other malignant cutaneous tumors showed a complete (<jats:italic>n<\/jats:italic>=15\/27, 56%) or partial (<jats:italic>n<\/jats:italic>=3\/27, 11%) response. Fewer non\u2010responders were seen at an Npe6 dose level of 1.65\u2003mg\/kg or higher. Only 2 of 14 patients experienced an adverse event that was definitely related to NPe6 administration. Photosensitivity resolved within 1 week of NPe6 dosing in 12 of 14 patients. Analysis of serum levels of 11 individual patients indicated that a two\u2010compartment model with a residual phase best fits the data. The mean \u03b1, \u03b2, and terminal half\u2010lives were 8.63\u00b12.92, 105.90\u00b137.59 and 168.11\u00b153.40\u2003h (\u00b11\u2003SD), respectively. The observed mean volume of distribution was 5.94\u00b12.55\u2003l, and the mean clearance was 0.0394\u00b10.0132\u2003l\/h. These values were independent of the dose administered.<\/jats:p><jats:p><jats:bold>Conclusion: <\/jats:bold> The photosensitizer, NPe6, was well tolerated with minimal phototoxic side effects, and demonstrated preliminary efficacy against cutaneous malignancies.<\/jats:p>","DOI":"10.1111\/j.1600-0781.2005.00138.x","type":"journal-article","created":{"date-parts":[[2005,3,7]],"date-time":"2005-03-07T09:22:06Z","timestamp":1110187326000},"page":"72-78","source":"Crossref","is-referenced-by-count":38,"title":["Pharmacokinetics and clinical effects of mono\u2010<scp>l<\/scp>\u2010aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces"],"prefix":"10.1111","volume":"21","author":[{"given":"Andrew L.","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Juarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roblee","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Volz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Albertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,3,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.12.889"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.1994.01880320054012"},{"issue":"1","key":"e_1_2_6_4_2","first-page":"36","article-title":"Hematoporphyrin photodynamic therapy","volume":"101","author":"Gluckman JL.","year":"1991","journal-title":"is there truly a future in head and neck oncology? Reflections on a 5-year experience"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/019459989010200304"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.1990.01870110039003"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(95)90035-7"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00063198-200307000-00010"},{"key":"e_1_2_6_9_2","first-page":"829","article-title":"Endobronchial photodynamic therapy for the treatment of lung cancer","volume":"11","author":"Metz JM","year":"2001","journal-title":"Chest Surg Clin North Am"},{"key":"e_1_2_6_10_2","first-page":"3985","article-title":"Tissue distribution and photosensitizing properties of mono\u2010l\u2010aspartyl chlorin e6 in a mouse tumor model","volume":"50","author":"Gomer CJ","year":"1990","journal-title":"Cancer Res"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-1097.1989.tb09193.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.1900090203"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.1900090204"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-1097.1991.tb08468.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-1097.1987.tb04849.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-1097.1987.tb04815.x"},{"key":"e_1_2_6_17_2","first-page":"475","volume-title":"Photodynamic therapy and biomedical lasers","author":"Brown SB","year":"1992"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1011-1344(96)00009-7"},{"key":"e_1_2_6_19_2","first-page":"526","volume-title":"Photodynamic therapy and biomedical lasers","author":"Kessel D","year":"1992"},{"key":"e_1_2_6_20_2","first-page":"2890","article-title":"Metabolic properties and photosensitizing responsiveness of mono\u2010l\u2010aspartyl chlorin e6 in a mouse tumor model","volume":"52","author":"Ferrario A","year":"1992","journal-title":"Cancer Res"},{"key":"e_1_2_6_21_2","first-page":"441","volume-title":"Photodynamic Therapy and Biomedical Lasers","author":"Allen RP","year":"1992"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1201\/b14095"},{"key":"e_1_2_6_23_2","first-page":"446","volume-title":"Photodynamic Therapy and Biomedical Lasers","author":"Volz W","year":"1992"},{"key":"e_1_2_6_24_2","first-page":"2741","article-title":"Photodynamic therapy using mono\u2010l\u2010aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease","volume":"4","author":"Taber SW","year":"1998","journal-title":"a phase I clinical study"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-1097.1989.tb09191.x"},{"key":"e_1_2_6_26_2","first-page":"136","article-title":"Pilot study of topical delivery of mono\u2010l\u2010aspartyl chlorin e6 (NPe6)","volume":"93","author":"Wong TW","year":"2003","journal-title":"implication of topical NPe6-photodynamic therapy"}],"container-title":["Photodermatology, Photoimmunology &amp; Photomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0781.2005.00138.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0781.2005.00138.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T20:21:45Z","timestamp":1696969305000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0781.2005.00138.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,7]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["10.1111\/j.1600-0781.2005.00138.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0781.2005.00138.x","archive":["Portico"],"relation":{},"ISSN":["0905-4383","1600-0781"],"issn-type":[{"value":"0905-4383","type":"print"},{"value":"1600-0781","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3,7]]}}}